1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hindustan Bio Sciences Limited

Hindustan Bio Sciences Limited

BBSE:HINDBIO
6.90
INR
-0.08
(-1.15%)
-0.20EPS
73.60MMarket Cap
Hindustan Bio Sciences Limited
BSE:HINDBIO
(Bombay Stock Exchange)

Recent

price

6.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
3.64
2.5
3.8
2.2
0.74
1.23
0.99
1.01
3.46
1.88
0.98
0.41
0.85
1.08
0.81
0.75
0.37
Revenue per Share
0.01
-0.08
-0.7
-0.97
-1.42
-2.04
-0.48
-2.22
0.11
0.08
-0.92
-0.5
-0.04
0.06
0.1
-0.08
-0.2
Basic EPS, GAAP
0.25
-0.38
- -
-0.45
-0.27
0.44
-0.16
-0.23
-1.3
0.8
0.73
-0.34
-0.05
-1.47
0.03
-0.14
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
9.96
9.88
9.18
8.21
6.74
4.7
4.22
2
2.11
2.19
1.27
0.77
0.73
0.78
0.88
0.81
- -
Book Value per Share
9.96
9.88
9.18
8.21
6.74
4.7
4.22
2
2.11
2.19
1.27
0.77
0.73
0.78
0.88
0.81
- -
Tangible Book Value per Share
10
11
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
Basic Weighted Avg Shares
37
27
39
23
8
13
10
10
35
19
10
4
9
10
8
7
4
Sales/Revenue/Turnover
1.45
-2.33
-15.86
-39.63
-179.72
-10.32
-27.53
-0.97
3.55
6.39
-14.77
-108.55
-6.4
5.07
12.25
-10.61
-60.68
Operating Margin (%)
3
3
3
2
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-7
-10
-15
-21
-5
-23
1
1
-9
-5
- -
1
1
-1
-2
Net Income, GAAP
73.88
- -
- -
- -
- -
- -
- -
- -
2.09
30.56
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
0.22
-3.2
-18.43
-44.03
-193.15
-165.69
-48.55
-220.65
3.1
4.2
-93.49
-123.97
-4.65
5.54
12.39
-10.7
-53.86
Profit Margin (%)
8
5
18
13
4
-2
-5
-5
10
7
-4
-6
-6
9
10
8
- -
Working Capital
1
1
1
6
10
4
5
8
25
17
7
11
11
26
25
23
- -
LT Debt
102
101
94
84
69
48
43
21
22
22
13
8
7
8
9
8
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
2.73
1.66
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
2.43
1.56
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-0.85
-7.34
-11.13
-18.99
-35.6
-10.74
-71.3
5.22
3.67
-52.96
-49.49
-5.28
7.43
11.79
-9.12
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
23
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
54
80
74

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
8
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-12.88%
-6.66%
-8.73%
Free Cash Flow
200.4%
359.43%
-600.37%
Net Income, GAAP
-158.97%
-96.55%
-178.27%
Sales/Revenue/Turnover
17.07%
7.64%
-9.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4
4
- -
4
8
2026
3
- -
4
- -
7
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.08
0.08
-0.04
0.11
0.1
2026
0.01
-0.06
0.08
-0.11
-0.08
2027
-0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hindustan Bio Sciences Limited engages in the manufacturing, marketing, and sale of pharmaceutical and biotechnology products primarily in India with exports to global markets. The company produces a wide range of premium finished dosage forms, including dry and liquid injectables, liquid and dry syrups, eye/ear/nasal drops, pre-filled syringes, non-sterile and sterile ointments, tablets, and capsules; it also offers the niche nephrology drug recombinant human erythropoietin (EPOVIN), which it began marketing extensively after obtaining import license and conducting clinical trials in 2007. Founded in 1991 and headquartered in Hyderabad, Telangana, the company maintains world-class manufacturing facilities approved by several regulatory authorities and previously sourced bulk drugs and intermediates before diversifying into finished formulations. In recent developments, the company appointed new independent directors Gorrela Pratheek Reddy and Bodeddula Nagi Reddy for five-year terms commencing September 30, 2024, following the expiry of prior independent directors' terms; it also saw changes in key managerial personnel, including a new company secretary and chief financial officer during fiscal 2023-24, alongside reporting revenue growth to Rs 105.27 lakhs and a net profit of Rs 5.76 lakhs for the year ended March 31, 2024.